Search

Displaying results 1051 - 1060 of 8195 in total
  1. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … [L56116, A275467] Marnetegragene autotemcel, also known as marne-cel, is an autologous hematopoietic stem cell-based gene therapy created from the patient's own hematopoietic stem cells.

  2. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative. … Both can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks.

  3. Drug

    Diethyltoluamide

    go.drugbank.com/drugs/DB11282
    Approved

    Diethyltoluamide (DEET) is the common active ingredient in many insect repellent products. It is widely used to repel biting pests such as mosquitoes and ticks. Every year, DEET formulations are used to protect populations from mosquito-...

  4. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    [A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Cinnarizine

    go.drugbank.com/drugs/DB00568
    ApprovedInvestigational

    Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. … First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  6. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals.

  7. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  8. Drug

    Trovafloxacin

    go.drugbank.com/drugs/DB00685
    ApprovedWithdrawn

    Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Guanabenz

    go.drugbank.com/drugs/DB00629
    ApprovedWithdrawn

    Guanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates